全文获取类型
收费全文 | 2907篇 |
免费 | 210篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 56篇 |
儿科学 | 54篇 |
妇产科学 | 38篇 |
基础医学 | 421篇 |
口腔科学 | 76篇 |
临床医学 | 312篇 |
内科学 | 676篇 |
皮肤病学 | 29篇 |
神经病学 | 227篇 |
特种医学 | 246篇 |
外科学 | 471篇 |
综合类 | 12篇 |
一般理论 | 1篇 |
预防医学 | 131篇 |
眼科学 | 38篇 |
药学 | 151篇 |
中国医学 | 9篇 |
肿瘤学 | 185篇 |
出版年
2023年 | 34篇 |
2022年 | 101篇 |
2021年 | 185篇 |
2020年 | 104篇 |
2019年 | 126篇 |
2018年 | 128篇 |
2017年 | 86篇 |
2016年 | 109篇 |
2015年 | 132篇 |
2014年 | 160篇 |
2013年 | 176篇 |
2012年 | 248篇 |
2011年 | 244篇 |
2010年 | 110篇 |
2009年 | 101篇 |
2008年 | 177篇 |
2007年 | 154篇 |
2006年 | 149篇 |
2005年 | 143篇 |
2004年 | 111篇 |
2003年 | 101篇 |
2002年 | 95篇 |
2001年 | 16篇 |
2000年 | 17篇 |
1999年 | 25篇 |
1998年 | 12篇 |
1997年 | 3篇 |
1996年 | 15篇 |
1995年 | 5篇 |
1994年 | 3篇 |
1993年 | 2篇 |
1992年 | 6篇 |
1991年 | 4篇 |
1990年 | 4篇 |
1989年 | 2篇 |
1987年 | 5篇 |
1985年 | 3篇 |
1977年 | 5篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1974年 | 4篇 |
1973年 | 3篇 |
1972年 | 1篇 |
1971年 | 3篇 |
1970年 | 4篇 |
1969年 | 2篇 |
1968年 | 2篇 |
1903年 | 2篇 |
1901年 | 1篇 |
1898年 | 1篇 |
排序方式: 共有3133条查询结果,搜索用时 31 毫秒
71.
OBJECTIVE: To investigate the contribution of clinical ex vivo expansion protocols to replicative aging of human chondrocytes. METHODS: Primary human chondrocytes were cultured as monolayers after isolation from 7 articular cartilage specimens. Cells were passaged corresponding to 12-19 cell population doublings (cpd). Aliquots of the cells were collected from each passage and analyzed for telomere length and telomerase activity. RESULTS: The rate of telomere shortening was heterogeneous, ranging from 147 to 431 bp/cpd (mean +/- SD 305 +/- 122). Telomerase activity was detected at various time points during passaging in 5 of 7 primary chondrocytes analyzed, but not in native human articular cartilage specimens. According to our data, an 8-10-fold ( approximately 3 cpd) ex vivo expansion of articular chondrocytes, as typically performed for transplantation procedures, leads to telomere erosion in the range of 900 bp. This is comparable with 30 years of aging based on the in vivo rate of telomere shortening of 30 bp/year recently found in chondrocytes. CONCLUSION: If telomere shortening is an important determinant of aging in human articular cartilage, an additional telomere loss due to ex vivo expansion might affect the incidence or time of onset of age-related cartilage disorders. However, given the limited extent of expansion performed in the clinical setting to date, a significant telomere-mediated increase in the risk of malignant transformation or replicative exhaustion of the transplanted cells seems unlikely. 相似文献
72.
Nir Uriel Diego Medvedofsky Teruhiko Imamura Jiri Maly Eric Kruse Peter Ivák Poornima Sood Roberto M. Lang Francesco Maffessanti Dominik Berliner Johann Bauersachs Axel Haverich Michael Želízko Ivan Netuka Jan D. Schmitto 《Journal of cardiac failure》2019,25(1):36-43
Background
The Heartmate 3 (HM3) is a Conformiteé Européenne mark–approved left ventricular (LV) assist device (LVAD) with fully magnetically levitated rotor and features consisting of a wide range operational speeds, wide flow paths, and artificial pulse. We performed a hemodynamic-echocardiographic speed optimization evaluation in HM3-implanted patients to achieve optimal LV- and right ventricular (RV) shape.Methods and Results
Sixteen HM3 patients underwent pump speed ramp tests with right heart catheterization. Three-dimensional echocardiographic (3DE) LV and RV datasets (Philips) were acquired, and volumetric (Tomtec) and shape (custom software) analyses were performed (LV: sphericity, conicity; RV: septal and free-wall curvatures). Data were recorded at up to 13 speed settings. Speed changes were in 100-rpm steps, starting at 4600 rpm and ramping up to 6200 rpm. 3DE was feasible in 50% of the patients. Mean original speed was 5306 ± 148 rpm. LV end-diastolic (ED) diameter (?0.15 ± 0.09 cm/100 rpm) and volumes (ED: 269 ± 109 mL to 175 ± 90 mL; end-systolic [ES]: 234 ± 111 mL to 146 ± 81 mL) progressively decreased as the shape became less spherical and more conical; RV volumes initially remained stable, but at higher speeds increased (ED: from 148 ± 64 mL to 181 ± 92 mL; ES: 113 ± 63 mL to 130 ± 69 mL). On average, the RV septum became less convex (bulging toward the LV) at the highest speeds.Conclusions
LV and RV shape changes were noted in HM3-supported patients. Although a LV volumetric decrease and shape improvement was consistently noted, RV volumes grew in response to increase in speed above a certain point. A next concern would be whether understanding of morphologic and function changes in LV and RV during LVAD speed change assessed with the use of 3DE helps to optimize LVAD speed settings and improve clinical outcomes. 相似文献73.
MacDonald TM Reginster JY Littlejohn TW Richard D Lheritier K Krammer G Rebuli R 《Journal of hypertension》2008,26(8):1695-1702
OBJECTIVES: Nonsteroidal anti-inflammatory drugs vary in their impact on blood pressure and the effect of lumiracoxib 100 mg once daily has not been studied previously. To examine whether lumiracoxib 100 mg once daily would result in lower 24-h mean systolic ambulatory blood pressure than ibuprofen 600 mg three times daily in osteoarthritis patients with controlled hypertension, a 4-week, randomized, double-blind, parallel-group study was conducted in 79 centres in nine countries. METHODS: Hypertensive osteoarthritis patients of 50 years at least whose office blood pressure was less than 140/90 mmHg on stable antihypertensive treatment were randomized to lumiracoxib (n = 394) 100 mg once daily or ibuprofen 600 mg three times daily (n = 393) and 24-h ambulatory blood pressure monitoring was performed at baseline and end of study. The primary outcome measure was a comparison of the change in 24-h mean systolic ambulatory blood pressure from baseline to week 4. Secondary analyses included other blood pressure-related endpoints and efficacy (pain) measurements. RESULTS: Compared with baseline, the 24-h mean systolic ambulatory blood pressure (least square mean) decreased in lumiracoxib-treated patients (-2.7 mmHg) and increased in ibuprofen-treated patients (+2.2 mmHg) at 4 weeks, estimated difference -5.0 mmHg (95% confidence interval -6.1 to -3.8) in favour of lumiracoxib. The 24-h mean diastolic ambulatory blood pressure changes were -1.5 mmHg (lumiracoxib), +0.5 mmHg (ibuprofen), difference -2.0 mmHg (95% confidence interval -2.7 to -1.3). Efficacy results were comparable. CONCLUSIONS: Treatment with lumiracoxib 100 mg once daily resulted in clinically significant lower blood pressure compared with ibuprofen 600 mg three times daily in osteoarthritis patients with well controlled hypertension. 相似文献
74.
75.
The use of allogeneic hematopoietic stem cell transplantation for the treatment of chronic myeloid leukemia (CML) patients has changed dramatically during the past decade. It was the standard of care for all younger CML patients with a compatible donor before the introduction of imatinib. It is used now as a rescue treatment for patients for whom tyrosine kinase inhibitors have failed. Both treatments, tyrosine kinase inhibitors and allogeneic transplantation, are very powerful and able to control the disease in the long-term. It is therefore of great importance to know the place of each therapy and to integrate allogeneic hematopoietic stem cell transplantation in a risk-adapted way into the treatment plan of each individual patient. 相似文献
76.
Increased insulin clearance in peroxisome proliferator-activated receptor gamma2 Pro12Ala 总被引:2,自引:0,他引:2
Tschritter O Fritsche A Stefan N Haap M Thamer C Bachmann O Dahl D Maerker E Teigeler A Machicao F Häring H Stumvoll M 《Metabolism: clinical and experimental》2003,52(6):778-783
The Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPARgamma(2)) is associated with reduced risk for type 2 diabetes. Although increased insulin sensitivity of glucose disposal and lipolysis has been reported, the exact mechanism by which the risk reduction is conferred is not clear. Because the conclusion of greater insulin sensitivity hinged upon lower insulin levels in some studies, it is possible that more efficient insulin clearance is involved. We therefore estimated insulin clearance during a euglycemic hyperinsulinemic clamp (insulin infusion rate divided by steady-state insulin concentration, 229 normal glucose tolerant [NGT] subjects), an oral glucose tolerance test (OGTT) (mean C-peptide divided by mean insulin concentrations, 406 NGT, 54 impaired glucose tolerant or mildly diabetic subjects), and a hyperglycemic clamp (120 minutes, 10 mmol/L, C-peptide divided by insulin in the steady-state, 56 NGT subjects). In the carriers of the Ala allele (prevalence approximately 24%), insulin clearance in all 3 protocols was significantly greater ( approximately 10%), than in controls. While the results from the euglycemic clamp reflect both hepatic and peripheral insulin clearance, those from the OGTT and the hyperglycemic clamp reflect mainly hepatic insulin extraction. Free fatty acids (FFA) during the steady state of the euglycemic hyperinsulinemic clamp were significantly lower in carriers of the Ala allele (26 +/- 5 micromol/L) than in controls (46 +/- 3 micromol/L, P =.02). In conclusion, the Pro12Ala polymorphism is associated with increased insulin clearance. This could be the result of reduced FFA delivery, which has been shown to improve hepatic insulin removal and sensitivity. Because PPARgamma(2) is mainly expressed in adipose tissue, one of the main regulatory effects of the polymorphism may well be the more efficient suppression of (possibly intra-abdominal) lipolysis. 相似文献
77.
Carlos Franciney Moreira Vasconcelos Nívea Maria da Cunha Ferreira Nayanne Hardy Lima Pontes Thomas Dominik de Sousa dos Reis Ricardo Basto Souza Francisco Eduardo Arago Catunda Junior Lissiana Magna Vasconcelos Aguiar Rodrigo Maranguape Silva da Cunha 《Basic & clinical pharmacology & toxicology》2020,127(4):287-302
Parkinson's disease is a neurodegenerative disorder that affects the central nervous system and is mainly characterized by the loss of dopaminergic neurons and pro‐oxidant mechanisms. Eugenol has been widely studied due to its anti‐inflammatory and antioxidant activities, making it a promising neuroprotective agent. This study aimed to investigate the effects of eugenol and its combined action with levodopa in the 6‐hydroxydopamine‐induced Parkinson's disease model. Wistar rats were subjected to intrastriatal injection of 6‐hydroxydopamine (21 μg) and then treated with eugenol (0.1, 1, or 10 mg/kg), levodopa (25 mg/kg) or their combination (eugenol 10 mg/kg + levodopa 12.5 mg/kg) orally for 14 days. On the 14th day, the animals were subjected to behavioural tests, and after euthanization and dissection of the brain areas, neurochemical analyses were performed. The results showed that eugenol reduced the oxidative stress and behavioural disturbances induced by 6‐hydroxydopamine. The eugenol and levodopa combination was more effective in some behavioural parameters and body‐weight gain in addition to promoting an increase in reduced glutathione levels compared to levodopa alone. Thus, the neuroprotective activity of eugenol was observed against motor and neurochemical disorders. Additionally, the eugenol and levodopa combination was promising when compared to conventional treatment. 相似文献
78.
Dominik Natalia Galassi Deforie Valentina Cortese Andrea Houlden Henry 《Journal of neurology》2021,268(3):1119-1126
Journal of Neurology - The ataxias are a group of disorders that manifest with balance, movement, speech and visual problems. They can arise due to dysfunction of the cerebellum, the vestibular... 相似文献
79.
80.
Fabian Brunk Andreas Moritz Annika Nelde Tatjana Bilich Nicolas Casadei Sabine A. K. Fraschka Jonas S. Heitmann Sebastian Hörber Andreas Peter Hans-Georg Rammensee Harpreet Singh Juliane Walz Dominik Maurer Claudia Wagner 《European journal of immunology》2021,51(11):2651-2664
Both B cells and T cells are involved in an effective immune response to SARS-CoV-2, the disease-causing virus of COVID-19. While B cells—with the indispensable help of CD4+ T cells—are essential to generate neutralizing antibodies, T cells on their own have been recognized as another major player in effective anti-SARS-CoV-2 immunity. In this report, we provide insights into the characteristics of individual HLA-A*02:01- and HLA-A*24:02-restricted SARS-CoV-2-reactive TCRs, isolated from convalescent COVID-19 patients. We observed that SARS-CoV-2-reactive T-cell populations were clearly detectable in convalescent samples and that TCRs isolated from these T cell clones were highly functional upon ectopic re-expression. The SARS-CoV-2-reactive TCRs described in this report mediated potent TCR signaling in reporter assays with low nanomolar EC50 values. We further demonstrate that these SARS-CoV-2-reactive TCRs conferred powerful T-cell effector function to primary CD8+ T cells as evident by a robust anti-SARS-CoV-2 IFN-γ response and in vitro cytotoxicity. We also provide an example of a long-lasting anti-SARS-CoV-2 memory response by reisolation of one of the retrieved TCRs 5 months after initial sampling. Taken together, these findings contribute to a better understanding of anti-SARS-CoV-2 T-cell immunity and may contribute to paving the way toward immunotherapeutics approaches targeting SARS-CoV-2. 相似文献